Cancer Immunology, Immunotherapy

, Volume 30, Issue 6, pp 342–350

Tumor-infiltrating lymphocytes from nonrenal urological malignancies

  • Gabriel P. Haas
  • Diane Solomon
  • Steven A. Rosenberg
Original articles

DOI: 10.1007/BF01786883

Cite this article as:
Haas, G.P., Solomon, D. & Rosenberg, S.A. Cancer Immunol Immunother (1990) 30: 342. doi:10.1007/BF01786883

Summary

Tumor-infiltrating lymphocytes (TIL) were isolated from 15 of 20 surgical specimens of transitional cell carcinoma of the urinary bladder, prostate cancer, testicular cancer, Wilms tumor and adrenal cancer. Expansion was carried out in four different culture conditions, each containing 1000 U/ml interleukin-2: RPMI medium with or without 20% (by volume) of lymphokine-activated killer cell (LAK) supernatant and AIM V medium with or without 20% LAK supernatant. The resultant cell populations were then assayed for cytotoxicity against a variety of autologous and allogeneic tumor targets and phenotypic analysis was performed with fluorescein-labeled monoclonal antibodies. TIL growth was unrelated to the initial percentage of lymphocytes or tumor cells present in the enzymatically dispersed specimens or whether fresh or cryopreserved tissue was utilized. Better growth was seen in AIM V than in RPMI medium (P = 0.013); the beneficial effect of the addition of LAK supernatant to RPMI was indicated (P = 0.065), and the addition of LAK supernatant to AIM V did not improve the ability to culture TIL (P = 0.5) from these cancers. TIL in long-term culture were predominantly CD3+. The ratio of CD4+/CD8+ cells varied with time in culture and culture medium, but most cultures eventually became CD4+. Cells bearing B cell, natural killer cell, and macrophage markers disappeared early in culture. Overall 14/15 TIL samples were lytic against one of the autologous and allogeneic targets tested, but specific lysis against the autologous tumor from which it was derived was seen in only one TIL culture originating from a bladder cancer. Our results suggest that TIL can be expanded to therapeutic levels from a variety of urological malignancies and that their potential role in future therapy should be further explored.

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Gabriel P. Haas
    • 1
  • Diane Solomon
    • 2
  • Steven A. Rosenberg
    • 1
  1. 1.Surgery BranchNational Institutes of HealthBethesdaUSA
  2. 2.Section of Cytopathology, Laboratory of Pathology, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations